Philips, bioMérieux to develop
AMSTERDAM, The Netherlands, MARCY
L’ETOILE, France – Royal Philips Electronics and bioMérieux announced
that they have signed an agreement to jointly develop fully automated
handheld diagnostic testing solutions for hospital use that can be
deployed at the point-of-care – i.e. close to the patient.
The collaboration aims to improve diagnosis and management of disease in
critical care settings within hospitals (for example, Emergency
Departments, Coronary Units and Intensive Care Units (ICUs)).
“Philips is convinced that point-of-care testing in hospital critical
care settings will play a major part in improving patient outcomes and
reducing healthcare costs. It is an excellent fit with our leading
market position in critical care settings and our holistic care cycle
approach to, for example, cardiac care,” said Steve Rusckowski,
Executive Vice President and Chief Executive Officer, Philips
“Their combined knowledge of medical technology, biomarker assays and
clinical workflows, coupled with their joint understanding of the
relevant markets, stakeholders and channels, puts Philips and bioMérieux
in a commanding position to drive forward a paradigm change in critical
care decision-making,” said Rusckowski.
“We are very pleased to be partnering with Philips, which has a strong
tradition in innovating patient care, and our collaboration will result
in superb products able to rapidly deliver high medical value results to
clinicians,” said Stéphane Bancel, bioMérieux Chief Executive Officer.
“We will be leveraging the strong synergies between our VIDAS biology
expertise and Philips’ unique engineering and technology capabilities.
This new point-of-care testing device will allow us to enter a market
that is growing at about 10% a year.”
This new alliance unites Philips’ existing strengths in medical
technology, patient monitoring and healthcare IT, including solutions
aimed at helping clinicians to make more informed decisions, with
bioMérieux’s expertise in the development of biological assays and its
extensive knowledge of cardiovascular and infectious disease markers.
A product development program is under way and the first milestone is
expected in 2010. As part of the agreement, bioMérieux will have access
to Philips’ proprietary Magnotech technology for hospital-based
point-of-care testing applications. Commercial solutions resulting from
the partnership will be co-branded by Philips and bioMérieux, with
bioMérieux being the exclusive distributor worldwide. The two companies
intend to have products on the market by 2013.
In critical-care settings, such as Emergency Departments within
hospitals, there is a persistent clinical need for diagnostic solutions
that enable fast and accurate patient triage – for example, diagnosing
acute coronary syndromes (e.g. a heart attack) to enable faster
treatment and improve patient outcomes. The fully automated handheld
testing devices that will be developed jointly by Philips and bioMérieux
will be immunoassay-based and employ Philips’ new Magnotech biosensor
They are intended to assist clinicians in time-critical decision-making
by reducing delays involved in laboratory-based testing. Philips’
Magnotech biosensor platform has been shown to have the potential to
match the analytical performance of laboratory systems in terms of
accuracy and sensitivity.
Philips and bioMérieux are already major players in supplying
critical-care solutions for hospital environments, and the products
resulting from the partnership will complement both companies’
offerings. Philips’ current portfolio includes a full range of
diagnostic tools (e.g. medical imaging, ECG and vital function
monitoring) to support healthcare providers in identifying high-risk
cardiac patients during the early stages of disease.
BioMérieux is already recognized among clinicians for its high medical
value tests, which include the VIDAS range of cardiac emergency markers:
Troponin I Ultra, Myoglobin, CK-MB, D-Dimer and NT-proBNP. The solutions
co-developed with Philips will be complementary to VIDAS, giving
clinicians the option of point-of-care testing without compromising on
Posted Jan. 14, 2010